How do we find the right dose in immune-oncology trials? Is the traditional “maximum tolerated dose” approach still enough, or should we also focus on efficacy? In this episode of The Effective Statistician, I talk with Teppo Huttunen, a seasoned statistician and co-founder of the boutique CRO, Estimeds. We uncover the shortcomings of the conventional three-plus-three design and explain how the Bayesian Optimal Interval (BOIN) design gives us more flexibility and better insights. Teppo shares practical tips on dose optimization and highlights the critical role statisticians play in shaping smarter, evidence-based decisions for phase two trials. If you want to learn how we can balance safety, efficacy, and practical challenges in oncology studies, this episode is for you!
Source link
